<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071612</url>
  </required_header>
  <id_info>
    <org_study_id>MARIPOSA</org_study_id>
    <nct_id>NCT05071612</nct_id>
  </id_info>
  <brief_title>Parallel Arm Trial of AD109 and AD504 In Patients With OSA</brief_title>
  <acronym>MARIPOSA</acronym>
  <official_title>Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apnimed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study&#xD;
      to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in&#xD;
      Obstructive Sleep Apnea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AHI, combined AD109 dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AHI, combined AD504 dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AHI, combined atomoxetine dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>OSA - Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>AD109 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD109 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD504 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD504 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD109</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>AD109 Dose 1</arm_group_label>
    <arm_group_label>AD109 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD504</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>AD504 Dose 1</arm_group_label>
    <arm_group_label>AD504 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine Hydrochloride</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>Atomoxetine 1</arm_group_label>
    <arm_group_label>Atomoxetine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 to 65 years of age for men and 18-75 for women, inclusive, at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Mean AHI 10 to 45 events/h, inclusive&#xD;
&#xD;
          -  PGI-S: &gt;1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current clinically significant sleep disorder other than OSA&#xD;
&#xD;
          -  Clinically significant craniofacial malformation.&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery&#xD;
             disease or heart failure or hypertension requiring more than 2 medications for&#xD;
             control).&#xD;
&#xD;
          -  Participants with a history of using devices for OSA treatment, including CPAP, oral&#xD;
             or nasal devices, or positional devices, may enroll as long as the devices have not&#xD;
             been used for at least 2 weeks prior to first PSG and are not used during&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ron Farkas, MD</last_name>
    <phone>617-500-8880</phone>
    <email>info@apnimed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luigi Taranto, MD</last_name>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

